NCT04496219View on ClinicalTrials.gov

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

August 16, 2022

Study Completion Date

August 23, 2022

Conditions
Bladder Urothelial Carcinoma In SituRecurrent Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8Superficial Bladder Urothelial Carcinoma
Interventions
DEVICE

Acupuncture Therapy

Undergo acupuncture therapy

BIOLOGICAL

BCG Solution

Given by intravesical injection

OTHER

Best Practice

Receive standard of care symptom management

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT04496219 - Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter